Figure 2. Virologic outcomes in people switching to BIC/TAF/FTC from DTG/ABC/3TC (A) and boosted protease inhibitors (B) at week 48.12,13
This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.
Figure 2. Virologic outcomes in people switching to BIC/TAF/FTC from DTG/ABC/3TC (A) and boosted protease inhibitors (B) at week 48.12,13